Abstract:OBJECTIVE:To assess the efficacy and pathological change of fertility-sparing treatment with progestin for endometrial carcinoma (EC) of stage I a and complex atypical hyperplasia (CAH) and to observe the prognosis of the treatment.METHODS:Nine EC patients of stage I a and 21 CAH patients aged under 40 years who desired childbearing and retaining their fertility were enrolled into this study. All patients were given a daily oral high-dose of progestin with duration of treatment ranging from 6 to 9 months. Diagnostic curettage was performed every 3 months as a modality for seeing the histologic change of neoplastic tissues and endometrial tissue. A careful and long- term follow- up is necessary for patients with complete response (CR).RESULTS:During the first period of fertility-sparing management, according to histologic change, 5 EC patients and 18 CAH patients showed CR with no evidence of endometrial adenocarcinoma or hyperplasia, 2 EC patients and 2 CAH patients showed partial response with a regression to complex or simple hyperplasia without atypia, 2 EC patients and 1 CAH patient showed stable disease or progressive disease. Accordingly, a total of 26 patients showed CR (26 of 30 patients). The median time to CR was 6 months (range, 3 to 21 months) of progestin treatment. The median follow-up time was 55.5 months (range, 24 to 104 months) and all patients were alive. During follow-up, among the 26 patients with CR, 3 of 6 EC patients achieved CR recurred disease after a median time interval of 10 months (range, 6 to 51 months), 7 of 20 CAH patients achieved CR had recurrent disease after a median time interval of 12 months (range, 6 to 55 months). Four of 7 CAH with recurrent disease achieved CR to progestin re-treatment. Eight of 26 patients achieved CR continued a further 3 or 6 months of consolidation therapy, 3 of them had recurrent disease, the remaining 18 stopped progesterone treatment after CR and 7 patients had recurrent disease; there was no significant statistical difference between the two groups (P = 1.000). EC patients succeeded in 4 pregnancies, CAH patients succeeded in 10 pregnancies, they gave birth to 16 healthy babies in all.CONCLUSIONS:EC of stage I a and CAH had slow progression of symptoms. Progestin treatment in EC of stage I a and CAH patients was effective. A careful and long-term follow-up is required because of the substantial high rate of recurrence. Progestin re-treatment in most patients with recurrent endometrial cancer is effective and safe.

Clinicopathological Analysis Of Fertility-Sparing Treatment And Pregnancy Outcomes In Young Women With Early-Stage Endometrial Carcinoma

Fertility-preserving Treatment and Pregnancy Outcomes in the Early Stage of Endometrial Carcinoma.

Outcome of Conservative Treatment and Subsequent Assisted Reproductive Technology for Patients with Early-Stage Endometrial Adenocarcinoma and Poor Fertility Potential

[Effects of Pathological Assessment of Endometrial Tissue in Fertility-Sparing Treatment with Progestin for Endometrial Carcinoma of Stage I a and Complex Atypical Hyperplasia].

Clinical analysis of fertility-preserving treatment in patients with endometrial carcinoma

Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma

Fertility-sparing Therapy in Young Women with Early Stage Endometrioid Carcinoma

Fertility-sparing treatment of early endometrial cancer

Treatment Efficiency of Comprehensive Hysteroscopic Evaluation and Lesion Resection Combined with Progestin Therapy in Young Women with Endometrial Atypical Hyperplasia and Endometrial Cancer.

Outcomes and Prognosis of Early Endometrial Carcinoma in Young Patients with Hysteroscopy Combined Progesterone Therapy

Clinical Analysis of Conservative Treatment with Progestin in Young Women with Endometrial Carcinoma

Clinical Outcomes of Fertility-Sparing Treatments in Young Patients with Epithelial Ovarian Carcinoma

Fertility-sparing treatment in women with endometrial cancer

Analysis of Pregnancy-Associated Factors after Fertility-Sparing Therapy in Young Women with Early Stage Endometrial Cancer or Atypical Endometrial Hyperplasia

Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis

The pregnancy and oncology outcome of fertility-sparing management for synchronous primary neoplasm of endometrium and ovary

Fertility-preserving treatment for young women with early-stage endometrial cancer

[Analysis of Prognosis and Pregnancy Outcomes of Fertility-Preserving Treatment for Patients with Stage Ⅰa, Grade 2 Endometrial Cancer].

A Phase Ⅱ Study of Fertility-Sparing Treatment with Megestrol Acetate for Endometrial Carcinoma and Atypical Hyperplasia in Young Women

Ovarian Preservation in Young Patients with Early Stage Endometrial Carcinoma.

Endometrial adenocarcinoma in women 40 years old or younger by treatment with progestins: report of 6 cases and review of the literatures